^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

rosomidnar liposomal (PNT2258)

i
Other names: PNT 100, PNT100, PNT2258, PNT-2258
Associations
Trials
Company:
GSK
Drug class:
Bcl2 inhibitor
Related drugs:
Associations
Trials
3years
Safety and Efficacy of a DNA Oligonucleotide Therapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. (PubMed, Clin Lymphoma Myeloma Leuk)
PNT2258 was well-tolerated in a chemotherapy refractory DLBCL population. Despite demonstration of single-agent activity, ORR was lower than acceptable for further new therapy development.
Clinical • Journal
|
BCL2 (B-cell CLL/lymphoma 2)
|
rosomidnar liposomal (PNT2258)
over3years
A Phase 2 Study of PNT2258 for Treatment of Relapsed or Refractory B-Cell Malignancies. (PubMed, Clin Lymphoma Myeloma Leuk)
Clinically meaningful and durable activity with an acceptable safety profile was observed in participants with relapsed/refractory B-cell malignancies who received single-agent PNT2258.
P2 data • Journal
|
BCL2 (B-cell CLL/lymphoma 2)
|
rosomidnar liposomal (PNT2258)